Cingulate (CING) Stock Analysis
NASDAQHealthcareBiotechnology
What Cingulate does
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Key metrics
ETFs linked to CING
Broad-market and Healthcare sector ETFs an investor holding Cingulate is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how CING fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze CING in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Cingulate?
- Cingulate trades under the ticker CING on NASDAQ.
- Which exchange is CING listed on?
- CING is listed on NASDAQ.
- What sector does Cingulate operate in?
- Cingulate is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze CING in a portfolio?
- PortView shows CING's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.